Navigation Links
Dendreon Corp. (Nasdaq: DNDN) - Prostate Cancer Patients Benefit
Date:4/30/2009

VALLEY COTTAGE, N.Y., April 30 /PRNewswire/ -- Less than two weeks ago, early on April 15th, Stock Preacher, in their Stock Talk section, posted a Special Technical Report on Dendreon Corporation (Nasdaq: DNDN), which we have been watching since 2007, when we first learned about it.

On April 14, DNDN gapped open on positive news from the previous day's close of 7.30/shr, to 16.00/shr, ran to 22.00/shr and closed at 16.99/shr + 9.69 (132%) on 65,345,600/shrs on the day, and since has traded as high as 27.00/shr over the past several trading sessions. From a technical POV, DNDN has traded down to close the gap it posted on the opening on April 14. This is very positive and Bullish action.

When we go back to look at the Stock Talk coverage, the Red Roadmaster's analysis after the April 14, 2009 market action was overall Bullish: in the near term Very Bullish, mid-term Bullish, and long term Bullish.

That analysis has proven to be true and the shares are having a dramatic run here, with overhead resistance Nil, and strong underlying support 21.40.

Yesterday,(April 29, 2009) DNDN closed + 11.13/shr (95%) at 23.00 on 48,134,768/shrs., the high on the day was 27.00/.

Late Tuesday afternoon, the Company released data from a Phase III clinical study that showed Provenge extended the lives of men with advanced prostate cancer by an average of 4.1 months. According to published analysts, Dendreon should be able to file for regulatory approval during the Q-4 Y 2009, with possible approval during the first half of 2010.

This is Dendreon Corp (DNDN): Dendreon is developing therapeutic vaccines that boost the body's immune system to help it fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its lead candidate is Provenge, a therapeutic vaccine that targets prostate cancer. Dendreon is also working on a therapeutic vaccine called Neuvenge as a treatment for breast, colon, ovarian, and kidney cancers; and it has research programs investigating cancer-fighting monoclonal antibodies and small molecule drugs. Its partners for its antibody programs include Amgen and Genentech

For more updates on Dendreon Corp (Nasdaq: DNDN), and other Companies making news, visit us at http://StockPreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a wholly owned entity of Allan James Group, Inc., a financial public relations firm. Please read our report and visit our website, StockPreacher.com, for complete risks and disclosures.

Investors can view all of the daily updates for free by visiting: http://StockPreacher.com/

Julio Serrano of Stock Preacher is a member of the National Association of Securities Dealers, CRD number 1603068.


'/>"/>
SOURCE Stock Preacher
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. -Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET-
2. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
3. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
4. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
5. Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine
6. ComPsych(R) Corp. Announces Health at Work(SM) Award Winners: Sprint, Erie Insurance, City of Naperville and Green Hills Public Library
7. New Health Corp. Announces the Addition of Hannaford Bros., Kash N Karry and Sweet Bay Supermarkets to its Retail Outlets
8. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
9. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
10. Former State Representative Terry Parke Joins Secure Services Corp.
11. InstaCare Corp. Reviewing M&A Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: